Polyenes

Upsher-Smith Launches Isotretinoin Capsules

Retrieved on: 
Friday, June 25, 2021
Anti-acne preparations, Chemical compounds, Retinoids, Organic compounds, Clinical medicine, Enones, Isotretinoin, Polyenes, iPLEDGE program, Pregnancy, Tretinoin, Acne

Isotretinoin capsules can cause lifethreatening birth defects and is contraindicated in pregnancy.

Key Points: 
  • Isotretinoin capsules can cause lifethreatening birth defects and is contraindicated in pregnancy.
  • There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin capsules in any amount, even for short periods of time.
  • Isotretinoin capsules are available only through a restricted program called the iPLEDGE REMS.
  • Please refer to the full Prescribing Information, including Boxed Warning for Isotretinoin Capsules here .

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

Retrieved on: 
Wednesday, May 26, 2021
Antifungals, Polyenes, Companies based in Ahmedabad, Amphotericin B, TLC, Medical specialties, Cadila Healthcare, Infectious disease, Drugs, Health care

Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.

Key Points: 
  • Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.
  • With the recent surge of infections in India, AmphoTLC will address the countrys acute liposomal amphotericin B shortage.
  • The approval of AmphoTLC in India follows the conduct of complete due diligence by regulators in India based on the numerous years of development TLC has dedicated as well as its quality performance in the developed markets.
  • TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology and infectious diseases.

TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

Retrieved on: 
Tuesday, May 25, 2021
Infectious diseases, Medical specialties, Fungal diseases, Antifungals, Polyenes, Amphotericin B, Mucormycosis, Mycosis

AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis.

Key Points: 
  • AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis.
  • The increasing number of CAM cases has resulted in unprecedently high demand for liposomal amphotericin B, the key drug to treat mucormycosis, causing an acute shortage of the drug.
  • Exploitation by sellers on the black market, who are marking up the price of liposomal amphotericin B by three times, is further exacerbating the situation.
  • The registration allows for immediate importation of AmphoTLC as per approved usage and indication of liposomal amphotericin B in India, which includes mucormycosis, to help alleviate the urgent need for the drug.

Temsirolimus Injection Now Available from Fresenius Kabi

Retrieved on: 
Friday, May 21, 2021
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Macrolides, Polyenes, Antineoplastic drugs, Temsirolimus, Sirolimus, Fresenius, Health care, Clinical medicine, Medicine, Temsirolimus Injection, Fresenius Kabi, TEMSIROLIMUS INJECTION, FRESENIUS KABI

b"Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States.

Key Points: 
  • b"Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States.
  • Fresenius Kabi\xe2\x80\x99s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210521005009/en/\nTemsirolimus, for the treatment of renal cancer, is now available in the U.S. from Fresenius Kabi.
  • If alternatives cannot be used, dose modifications of Temsirolimus Injection are recommended.\nThis Important Safety Information does not include all the information needed to use Temsirolimus Injection safely and effectively.

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States

Retrieved on: 
Thursday, April 29, 2021
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Anti-acne preparations, Chemical compounds, Retinoids, Organic compounds, Alkenes, Enones, Isotretinoin, Polyenes, Ndo, Capsule, Tretinoin, Isotretinoin Oral Capsules, Teva, ISOTRETINOIN ORAL CAPSULES, TEVA

See \xe2\x80\x9cBefore taking isotretinoin capsules\xe2\x80\x9d\nDo not drive at night until you know if isotretinoin capsules have affected your vision.

Key Points: 
  • See \xe2\x80\x9cBefore taking isotretinoin capsules\xe2\x80\x9d\nDo not drive at night until you know if isotretinoin capsules have affected your vision.
  • Isotretinoin capsules may make your skin more sensitive to light.\nDo not share isotretinoin capsules with other people.
  • Your healthcare provider will do tests to check your liver before and during treatment with isotretinoin capsules.
  • Tell your healthcare provider if you are very thirsty or urinate more than usual.\nThe most common side effects of isotretinoin capsules include:\n'

Squalene Market to grow by Over $ 55 Million | Covid-19 Impact Analysis, Key Drivers, Trends, & Major Vendor Offerings| Technavio

Retrieved on: 
Tuesday, April 6, 2021
Chemistry, Natural sciences, Physical sciences, Immunology, Hydrocarbons, Molecular biology, Polyenes, Squalene, Toxicology, Speciality chemicals, Cosmetics

The global squalene market is expected to grow by USD 55.23 million, exhibiting a CAGR of over 7% during 2021-2025, according to Technavio's latest market report.

Key Points: 
  • The global squalene market is expected to grow by USD 55.23 million, exhibiting a CAGR of over 7% during 2021-2025, according to Technavio's latest market report.
  • Based on our research, the specialty chemicals sector witnessed a neutral impact due to the widespread growth of the COVID-19 pandemic.
  • The market is witnessing a high preference for multifunctional cosmetic products such as squalene oils and squalene moisturizers.
  • Reasons to Buy Squalene Market Report:
    The growth of the squalene marketacross Europe, APAC, North America, and ROW
    This report can be personalized according to your business needs.

Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne

Retrieved on: 
Monday, March 22, 2021
Organic compounds, Chemical compounds, Enones, Isotretinoin, Polyenes, Retinoids, Fortress Biotech, Contact lens, Scottsdale, Arizona, Health care

Stop using Accutane and call your healthcare provider if your hearing gets worse or if you have ringing in your ears.

Key Points: 
  • Stop using Accutane and call your healthcare provider if your hearing gets worse or if you have ringing in your ears.
  • If you wear contact lenses, you may have trouble wearing them during and after you stop treatment with Accutane.
  • Journey Medical Corporation (Journey Medical) is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.
  • Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO).

Global Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Analysis

Retrieved on: 
Thursday, March 18, 2021
Fungal diseases, Drugs, Chemical compounds, Antifungals, Polyenes, Sepsis, Candidiasis, Amphotericin B, Aspergillosis, Invasive candidiasis, Voriconazole, Systemic

DUBLIN, March 18, 2021 /PRNewswire/ -- The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 18, 2021 /PRNewswire/ -- The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the global systemic aspergillosis and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
  • The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.
  • Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others.

Insights on the Systemic Aspergillosis and Systemic Candidiasis Global Market to 2027 - by Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, March 15, 2021
Health, Other Health, Branches of biology, Fungal diseases, Infectious diseases, Antifungals, Polyenes, Sepsis, Mycosis, Candidiasis, Amphotericin B, Aspergillosis, Invasive candidiasis, Voriconazole

The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.
  • Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others.
  • Rise in prevalence of fungal diseases and increase in incidence of hospital-acquired fungal infection are the key factors driving the systemic aspergillosis and systemic candidiasis market.

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Retrieved on: 
Monday, February 15, 2021
Organic compounds, Chemical compounds, Antineoplastic drugs, Chloroarenes, Immunosuppressants, Macrolides, Polyenes, Drugs, Everolimus, Lenvatinib

LENVIMA plus everolimus also showed statistically significant improvements in PFS (HR=0.65 [95% CI: 0.53-0.80]; p

Key Points: 
  • LENVIMA plus everolimus also showed statistically significant improvements in PFS (HR=0.65 [95% CI: 0.53-0.80]; p
  • The safety profiles of both LENVIMA plus KEYTRUDA and LENVIMA plus everolimus were consistent with previously reported studies.
  • "KEYTRUDA plus LENVIMA demonstrated a median progression-free survival of nearly two years, and seven in 10 patients experienced an objective response.
  • Grade 5 TRAEs occurred in 1.1% of patients in the LENVIMA plus KEYTRUDA arm and 0.8% of patients in the LENVIMA plus everolimus arm, versus 0.3% of patients in the sunitinib arm.